[1]李爱玲,谢云,李瑾,等.体重指数和腰臀比预测非酒精性脂肪性肝病发病风险的比较[J].国际内分泌代谢杂志,2014,(02):135-137.[doi:10.3760/cma.j.issn.1673-4157.2014.02.018]
　Li Ailing,Xie Yun,Li Jin,et al.Comparison of body mass index and waist-to-hip ratio for predicting of non-alcoholic fatty liver disease[J].International Journal of Endocrinology and Metabolism,2014,(02):135-137.[doi:10.3760/cma.j.issn.1673-4157.2014.02.018]
点击复制

体重指数和腰臀比预测非酒精性脂肪性肝病发病风险的比较()
分享到：

《国际内分泌代谢杂志》[ISSN:1673-4157/CN:12-1383/R]

卷:
期数:
2014年02期
页码:
135-137
栏目:
短篇论著
出版日期:
2014-04-30

文章信息/Info

Title:
Comparison of body mass index and waist-to-hip ratio for predicting of non-alcoholic fatty liver disease
作者:
李爱玲; 谢云; 李瑾; 赵诗钰
300070　天津医科大学代谢病医院神经内科 　　
Author(s):
Li Ailing; Xie Yun; Li Jin; Zhao Shiyu.
Department of Neuropathy,The Metabolic Disease Hospital, Tianjin Medical University,Tianjin 300070,China Corresponding author：Xie Yun,Email: tjxieyun0108@sina.com
关键词:
非酒精性脂肪性肝病; 体重指数; 腰臀比
Keywords:
Non-alcoholic fatty liver disease; Body mass index; Waist-to-hip ratio
DOI:
10.3760/cma.j.issn.1673-4157.2014.02.018
摘要:
目的　分析非酒精性脂肪性肝病（NAFLD）的危险因素,探讨NAFLD与体重指数、腰臀比的关系。方法　选取天津医科大学代谢病医院住院患者及同期门诊患者共474例,依据2010年中国NAFLD诊疗指南,结合肝脏B超结果,将其分为NAFLD组（n =189）和非NAFLD组（n =285例）。回顾性分析两组患者腰臀比、体重指数、收缩压、舒张压、血脂谱等各项临床指标,采用多因素Logistic回归分析发生NAFLD的独立危险因素,并采用受试者工作特征曲线（ROC曲线）比较体重指数和腰臀比预测NAFLD的发病风险。结果　Logistic回归分析显示：腰臀比（P =0.000）、收缩压（P =0.029）、糖尿病病史（P =0.003）、总胆固醇（P =0.000）、甘油三酯（P =0.003）、高密度脂蛋白-胆固醇（P =0.015）为NAFLD的独立危险因素；ROC曲线结果显示,腰臀比的曲线下面积（AUC）、敏感性分别为0.825, 0.799,体重指数的 AUC、敏感性分别为0.755,0.593,P =0.000。结论　与体重指数升高相比,腰臀比升高的患者,发生NAFLD的风险更高,腰臀比较体重指数更能预测NAFLD的发生。
Abstract:
Objective　To investigate the risk factors of non-alcoholic fatty liver disease（NAFLD）, and the association of NAFLD with body mass index（BMI） and waist-to-hip ratio（WHR）. Methods　 474 in-patients and out-patients from The Metabolic Disease Hospital of Tianjin Medical University were divided into NAFLD group（n =189） and non-NAFLD group （n =285） according to the guidelines of prevention and treatment of NAFLD among Chinese adults and the results of liver ultrasonic images. Clinical indicators were analyzed and compared between groups. The independent risk factors were analyzed by multiple regression, and Logistic regression. The association of NAFLD with BMI and WHR were analyzed by the receiver operating characteristic curve（ROC curve）. Results　The independent risk factors for NAFLD were WHR（P =0.000）,systolic pressure（P =0.029）,history of diabetes mellitus （P =0.003）,total cholesterol （P =0.000）,triglyceride （P =0.003）,high density lipoprotein-cholesterol（P =0.015） in Logistic regression. The result of ROC curve showed that the AUC and sensitivity of WHR（0.825, 0.799） were higher than those of BMI（0.755,0.593）,P =0.000。Conclusion　 Compared with BMI, the risk of NAFLD increases more with the higher WHR and WHR is a better predictor of NAFLD than BMI.

参考文献/References:

　[1]　Vernon G,Baranova A,Younossi ZM. Systematic review：the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults[J]. Aliment Pharmacol Ther,2011,34（2）：274-285. 　
[2]　黄春明,李瑜元.非酒精性脂肪肝的流行病学[J].现代消化及介入诊疗,2009,14（4）：233-237. 　
[3]　Smith BW,Adams LA． Non-alcoholic fatty liver disease[J]．Crit Rev Clin Lab Sci,2011,48（3）：97-113. 　
[4]　Sanyal AJ,Chalasani N,Kowdley KV,et al. Pioglitazone,vitamin E,or placebo for nonalcoholic steatohepatitis[J]. N Engl J Med,2010,362（18）：1675-1685. 　
[5]　Angulo P. GI epidemiology： nonalcoholic fatty liver disease[J]. Aliment Pharmacol Ther,2007,25（8）：883-889. 　
[6]　Fan JG,Saibara T,Chitturi S,et al. what are the risk factors and settings of non-alcoholic fatty liver disease in Asia-Pacific?[J]. J Gastroenterol Hepatol,2007,22（6）：794-800. 　
[7]　Fan JG,Farrell GC. Epidemiology of non-alcoholic fatty liver disease in China[J]. J Hepatol,2009,50（1）：204-210. 　
[8]　中华医学会肝病学分会脂肪肝和酒精性脂肪肝病学组.非酒精性脂肪性肝病诊疗指南（2010年修订版）[J]. 胃肠病学和肝病学杂志.2010,19（6）：483-487. 　
[9]　de Alwis NM,Day CP. Non-alcoholic fatty liver disease：the mist gradually clears[J]. J Hepatol,2008,48 Suppl 1：S104-S112.
[10]　Cheung O,Sanyal AJ. Hepatitis C infection and nonalcoholic fatty liver disease[J]. Clin Liver Dis,2008,12（3）：573-585,viii-ix.
[11]　Ho JS,Cannaday JJ, Barlow CE,et al.Comparative relation of general,central,and visceral adiposity measures for coronary artery calcium in subjects without previous coronary events[J].Am J Cardiol,2009,104（7）：943-946.
[12]　Heitmann BL,Frederiksen P,Lissner L.Hip circumference and cardiovascular morbidity and mortality in men and women[J].Obes Res,2004,12（3）：482-487.

相似文献/References:

[1]张晓燕,陈莉明.儿童非酒精性脂肪性肝病研究进展[J].国际内分泌代谢杂志,2007,(04):289.
[2]贺肴,张弛,刘瑛,等.代谢正常肥胖合并非酒精性脂肪性肝病的临床特征及内皮功能研究[J].国际内分泌代谢杂志,2015,(03):163.[doi:10.3760/cma.j.issn.1673-4157.2015.03.005]
　He Yao,Zhang Chi,Liu Ying,et al.Clinical features and endothelial function in metabolically healthy obese patients with nonalcoholic fatty liver disease[J].International Journal of Endocrinology and Metabolism,2015,(02):163.[doi:10.3760/cma.j.issn.1673-4157.2015.03.005]
[3]邵金双,邸阜生.网膜素抗炎作用及与代谢相关疾病的关系[J].国际内分泌代谢杂志,2014,(01):29.[doi:10.3760/cma.j.issn.1673-4157.2014.01.008]
　Shao Jinshuang*,Di Fusheng ..Anti-inflammatory effect of omentin and its relationship with metabolic diseases[J].International Journal of Endocrinology and Metabolism,2014,(02):29.[doi:10.3760/cma.j.issn.1673-4157.2014.01.008]
[4]王兴纯,曲伸.胰高血糖素样肽-1受体激动剂与非酒精性脂肪性肝病[J].国际内分泌代谢杂志,2014,(01):40.[doi:10.3760/cma.j.issn.1673-4157.2014.01.011]
　Wang Xingchun*,Qu Shen.Glucagon like peptide-1 receptor agonist and nonalcoholic fatty liver disease[J].International Journal of Endocrinology and Metabolism,2014,(02):40.[doi:10.3760/cma.j.issn.1673-4157.2014.01.011]
[5]黄玥晔,曲伸.甲状腺激素受体：非酒精性脂肪性肝病的新靶点[J].国际内分泌代谢杂志,2014,(01):43.[doi:10.3760/cma.j.issn.1673-4157.2014.01.012]
　Huang Yueye,Qu Shen.Thyroid hormone receptor：a new target of nonalcoholic fatty liver disease[J].International Journal of Endocrinology and Metabolism,2014,(02):43.[doi:10.3760/cma.j.issn.1673-4157.2014.01.012]
[6]刘璐,李鸿.代谢调控的新靶点——Irisin[J].国际内分泌代谢杂志,2014,(02):109.[doi:10.3760/cma.j.issn.1673-4157.2014.02.011]
　Liu Lu,Li Hong..A new target in metabolic control--Irisin[J].International Journal of Endocrinology and Metabolism,2014,(02):109.[doi:10.3760/cma.j.issn.1673-4157.2014.02.011]
[7]蔡芸莹,苏恒.DPP-4在脂质代谢及非酒精性脂肪性肝病中的作用研究[J].国际内分泌代谢杂志,2014,(02):112.[doi:10.3760/cma.j.issn.1673-4157.2014.02.012]
　Cai Yun-ying,Su Heng..Effects of dipeptidyl peptidase-4 on lipid metabolism and nonalcoholic fatty liver disease[J].International Journal of Endocrinology and Metabolism,2014,(02):112.[doi:10.3760/cma.j.issn.1673-4157.2014.02.012]
[8]马卓奇 敖娜 都健.线粒体相关microRNA在非酒精性脂肪性肝病中的研究进展[J].国际内分泌代谢杂志,2019,39(05):307.[doi:10.3760/cma.j.issn.1673-4157.2019.05.005]
　Ma Zhuoqi,Ao Na,Du Jian.Research progress of mitochondria-related microRNA in non-alcoholic fatty liver disease[J].International Journal of Endocrinology and Metabolism,2019,39(02):307.[doi:10.3760/cma.j.issn.1673-4157.2019.05.005]
[9]张贺 杨立英 黄雯莉 王文昭 陈素凤 任路平.长链非编码RNA与非酒精性脂肪性肝病[J].国际内分泌代谢杂志,2020,40(04):241.[doi:10.3760/cma.j.issn.1673-4157.2020.04.006]
　Zhang He,Yang Liying,Huang Wenli,et al.Long non-coding RNA and non-alcoholic fatty liver disease[J].International Journal of Endocrinology and Metabolism,2020,40(02):241.[doi:10.3760/cma.j.issn.1673-4157.2020.04.006]
[10]邹家琦,丁雪洁,孙鹏,等.体重指数对胰岛分离产量及胰岛功能的影响[J].国际内分泌代谢杂志,2021,41(05):445.[doi:10.3760/cma.j.cn121383-20201204-12015]
　Zou Jiaqi,Ding Xuejie,Sun Peng,et al.The influence of body mass index on islet isolation outcome and function[J].International Journal of Endocrinology and Metabolism,2021,41(02):445.[doi:10.3760/cma.j.cn121383-20201204-12015]

备注/Memo

备注/Memo:
通信作者：谢云,Email:tjxieyun0108@sina.com
更新日期/Last Update: 2014-03-20